NCT07432308Completed
Liquid Biopsy Genotyping Using Oncomine Precision Assay GX in Advanced NSCLC
Evaluation of the Oncomine Precision Assay GX Method for Genotyping Circulating Tumor DNA in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Source: ClinicalTrials.gov · Last updated 6 Mar 2026
Brief summary (registry, in English)
This interventional clinical study evaluates the clinical utility and feasibility of the Oncomine Precision Assay GX method for genotyping circulating tumor DNA (ctDNA) in patients with advanced non-small cell lung cancer (NSCLC). Participants with advanced NSCLC undergo peripheral blood sampling as part of the study intervention. Circulating tumor DNA is analyzed using the Oncomine Precision Assay GX platform. Molecular findings obtained from liquid biopsy are compared with available standard diagnostic results from tumor tissue or other clinically indicated molecular testing methods. The aim of the study is to evaluate the feasibility, diagnostic performance, and clinical applicability of ctDNA genotyping using the Oncomine Precision Assay GX method in a real-world clinical setting and to assess its potential role in routine molecular diagnostics of advanced NSCLC.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 18 Feb 2026
- Start date
- 1 Feb 2024
- Primary completion date
- 31 Aug 2024
- Lead sponsor
- Institute of Oncology Ljubljana
- Diseases
- Lung cancer
- NCT number
- NCT07432308
What you commit to
- Study type: Interventional
- Participants enrolled: 22
- From 1 Feb 2024 to the primary completion date, 31 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any medical condition that, in the investigator's opinion, would interfere with participation or interpretation of results
Other
- Inability or unwillingness to provide written informed consent
- Insufficient blood sample for ctDNA analysis
Who the study is looking for
- Age ≥ 18 years
- Histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC)
- Planned or ongoing systemic treatment for advanced NSCLC according to standard clinical practice
- Availability of blood sample for circulating tumor DNA (ctDNA) analysis
- Ability to understand the study procedures and provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Oncology Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.